Wesley T O'Neal1,2, Saman Nazarian3, Alvaro Alonso4, Susan R Heckbert5,6, Viola Vaccarino7,4, Elsayed Z Soliman8,9. 1. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA. wesley.oneal@emory.edu. 2. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. wesley.oneal@emory.edu. 3. Department of Medicine, Division of Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 4. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 5. Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA. 6. Department of Epidemiology, University of Washington, Seattle, WA, USA. 7. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA. 8. Department of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 9. Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstract
PURPOSE: Atrial fibrillation is more prevalent in men than women. Due to these sex differences in atrial fibrillation susceptibility, we examined whether sex hormones have differing associations with atrial fibrillation risk in men and women. METHODS: This analysis included 4883 (mean age = 63 ± 10 years; 39% women; 64% non-white) participants from the Multi-Ethnic Study of Atherosclerosis. Sex hormones (total testosterone, bioavailable testosterone, estradiol, and sex hormone binding globulin) were measured at baseline (2000-2002) for all male and all postmenopausal female participants. Atrial fibrillation was ascertained by hospital discharge records, Medicare claims data, and study electrocardiograms through December 31, 2012. RESULTS: Over a median follow-up of 10.9 years, a total of 613 (13%) atrial fibrillation cases were detected. A higher incidence rate of atrial fibrillation was observed for males (n = 385, age-standardized incidence rate per 1000 person-years = 12.3, 95%CI = 11.1, 13.6) than females (n = 228, age-standardized incidence rate per 1000 person-years = 9.0, 95%CI = 7.9, 10.3). In men, higher bioavailable testosterone levels were associated with increased atrial fibrillation risk (HR = 1.32, 95%CI = 1.01, 1.74; p = 0.044; comparing 3rd to 1st tertile), while an association in the opposite direction was observed for women (HR = 0.81, 95%CI = 0.58, 1.13; p = 0.22; comparing 3rd to 1st tertile). Other hormones were not associated with atrial fibrillation in men or women. CONCLUSION: Higher levels of endogenous bioavailable testosterone contribute to atrial fibrillation development in men. The combination of endogenous bioavailable testosterone and other risk factors potentially are important for atrial fibrillation development in men.
PURPOSE: Atrial fibrillation is more prevalent in men than women. Due to these sex differences in atrial fibrillation susceptibility, we examined whether sex hormones have differing associations with atrial fibrillation risk in men and women. METHODS: This analysis included 4883 (mean age = 63 ± 10 years; 39% women; 64% non-white) participants from the Multi-Ethnic Study of Atherosclerosis. Sex hormones (total testosterone, bioavailable testosterone, estradiol, and sex hormone binding globulin) were measured at baseline (2000-2002) for all male and all postmenopausal female participants. Atrial fibrillation was ascertained by hospital discharge records, Medicare claims data, and study electrocardiograms through December 31, 2012. RESULTS: Over a median follow-up of 10.9 years, a total of 613 (13%) atrial fibrillation cases were detected. A higher incidence rate of atrial fibrillation was observed for males (n = 385, age-standardized incidence rate per 1000 person-years = 12.3, 95%CI = 11.1, 13.6) than females (n = 228, age-standardized incidence rate per 1000 person-years = 9.0, 95%CI = 7.9, 10.3). In men, higher bioavailable testosterone levels were associated with increased atrial fibrillation risk (HR = 1.32, 95%CI = 1.01, 1.74; p = 0.044; comparing 3rd to 1st tertile), while an association in the opposite direction was observed for women (HR = 0.81, 95%CI = 0.58, 1.13; p = 0.22; comparing 3rd to 1st tertile). Other hormones were not associated with atrial fibrillation in men or women. CONCLUSION: Higher levels of endogenous bioavailable testosterone contribute to atrial fibrillation development in men. The combination of endogenous bioavailable testosterone and other risk factors potentially are important for atrial fibrillation development in men.
Entities:
Keywords:
Atrial fibrillation; Epidemiology; Risk; Sex hormones
Authors: Morgana L Mongraw-Chaffin; Cheryl A M Anderson; Matthew A Allison; Pamela Ouyang; Moyses Szklo; Dhananjay Vaidya; Mark Woodward; Sherita Hill Golden Journal: J Clin Endocrinol Metab Date: 2015-01-30 Impact factor: 5.958
Authors: Jared W Magnani; Carlee B Moser; Joanne M Murabito; Lisa M Sullivan; Na Wang; Patrick T Ellinor; Ramachandran S Vasan; Emelia J Benjamin; Andrea D Coviello Journal: Circ Arrhythm Electrophysiol Date: 2014-03-08
Authors: Rita Rastogi Kalyani; Manuel Franco; Adrian S Dobs; Pamela Ouyang; Dhananjay Vaidya; Alain Bertoni; Susan M Gapstur; Sherita Hill Golden Journal: J Clin Endocrinol Metab Date: 2009-09-29 Impact factor: 5.958
Authors: Lu Wang; Moyses Szklo; Aaron R Folsom; Nancy R Cook; Susan M Gapstur; Pamela Ouyang Journal: Atherosclerosis Date: 2012-07-20 Impact factor: 5.162
Authors: Alvaro Alonso; Sunil K Agarwal; Elsayed Z Soliman; Marietta Ambrose; Alanna M Chamberlain; Ronald J Prineas; Aaron R Folsom Journal: Am Heart J Date: 2009-07 Impact factor: 4.749
Authors: David D McManus; Vanessa Xanthakis; Lisa M Sullivan; Justin Zachariah; Jayashri Aragam; Martin G Larson; Emelia J Benjamin; Ramachandran S Vasan Journal: Circulation Date: 2010-01-25 Impact factor: 29.690
Authors: Renate B Schnabel; Xiaoyan Yin; Philimon Gona; Martin G Larson; Alexa S Beiser; David D McManus; Christopher Newton-Cheh; Steven A Lubitz; Jared W Magnani; Patrick T Ellinor; Sudha Seshadri; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy Journal: Lancet Date: 2015-05-07 Impact factor: 79.321
Authors: Michael A Rosenberg; Molly M Shores; Alvin M Matsumoto; Petra Bůžková; Leslie A Lange; Richard A Kronmal; Susan R Heckbert; Kenneth J Mukamal Journal: Clin Cardiol Date: 2018-06-08 Impact factor: 2.882
Authors: Dylan Berger; Aaron R Folsom; Pamela J Schreiner; Lin Y Chen; Erin D Michos; Wesley T O'Neal; Elsayed Z Soliman; Alvaro Alonso Journal: Maturitas Date: 2019-03-31 Impact factor: 4.342
Authors: Thomas M Roston; Sunjidatul Islam; Nathaniel M Hawkins; Zachary W Laksman; Shubhayan Sanatani; Andrew D Krahn; Roopinder Sandhu; Padma Kaul Journal: CJC Open Date: 2021-09-14
Authors: Peng Hu; Jun Huang; Yi Lu; Murui Zheng; Haiyi Li; Xueru Duan; Hai Deng; Wenjing Zhao; Xudong Liu Journal: Front Cardiovasc Med Date: 2022-08-22